AXGN

AxoGen Inc (AXGN) | Rumor.io

AxoGen

AXGN

Attention (50-day avg)0%

Attention rank (50-day avg)#2,248

Bullish sentiment (50-day avg)87%

Price to earnings ratio-127.6

Market capitalization2.5B

Earnings per share-0.67

Dividend yield (TTM)—

Revenue (annual)225.2M

Net income (annual)-15.7M

Social

What share of all stock conversation is about AXGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% +0

Sep 10

Axogen, Inc. (AXGN) has agreed to acquire BioCircuit Technologies for $200M in cash, with the deal expected to close in Q4 2026.
The acquisition will add BioCircuit's FDA-cleared NerveTape sutureless nerve repair device to Axogen's portfolio, and is expected to boost growth and adjusted EBITDA margins in year one.
Axogen has priced a $208.7M public offering of common stock at $42.50 per share to fund the acquisition, with the company expected to have approximately zero long-term debt after the offering.

Generated by AI

Sentiment

Of the messages about AXGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +18.18	96.05% +23.35
Bearish	0%	0%	0% -18.18	3.95% -23.35

Bullish· Apr 28

Axogen's Q1 2026 earnings report showed strong revenue growth, with a 26.6% YoY increase to $61.5M, beating its own historical trajectory.
The company's revenue growth is accelerating, with a significant increase in Q1 2026 compared to Q4 2025, and a projected 20%+ growth for the full year, targeting $270M in revenue.
Axogen's cash position has increased to $103.6M, and the company is expecting to be free cash flow positive for the full year, with a gross margin in the 74-76% range.

Bearish· Dec 18

AxoGen, Inc. (AXGN) is an overhyped company with a cash-burning business model, trading at 12x revenue, and a target price of $5.07, implying an 82% downside.
AXGN has a high short interest, with a short entry at $32 and a target price of $17, indicating a significant bearish sentiment in the market.
A recent bearish article on Seeking Alpha has contributed to AXGN's decline, with the stock dropping by as much as 29% and reaching a low of $19.21, with a target price of $5.07.

Generated by AI

Topics

Of the messages about AXGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	0%	0%	4.08%	38.32%
Announcements	50%	50%	93.88%	47.31%
Analysts	50%	50%	2.04%	8.53%
Controversies	0%	0%	0%	0.47%
Earnings	0%	0%	0%	3.86%
Macro	0%	0%	0%	1.52%

Earnings· Aug 1

AxoGen, Inc. (AXGN) reported earnings that beat EPS estimates by $0.09, but missed revenue expectations.
The company's EPS results were in-line with estimates, but revenue came in lower than anticipated.
AxoGen, Inc. (AXGN) reported a loss in EPS, in-line with expectations, but the specific loss amount is not stated.

Announcements· Sep 10

Axogen, Inc. ($AXGN) has agreed to acquire BioCircuit Technologies for $200M in cash to expand its nerve repair portfolio.
The acquisition is expected to boost growth and adjusted EBITDA margins in year one, with closing expected in Q4 2026.
Axogen has priced a $208.7 million public offering at $42.50 per share to fund the BioCircuit acquisition, which sent shares down 5.2% in premarket trading.

Generated by AI

Community

Of the messages about AXGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	37.41%	44.64%
Newcomers	0%	0%	62.59%	55.36%

Regulars· Sep 10

Axogen, Inc. (AXGN) has agreed to acquire BioCircuit Technologies for $200M in cash, with the deal expected to close in Q4 2026, subject to conditions.
The acquisition is being funded by a $208.7M public offering of common stock, priced at $42.50 per share, with Axogen planning to offer 4.91M shares.
Analysts are positive on the deal, citing the addition of NerveTape, the first FDA-approved sutureless nerve repair device, which is expected to be accretive to revenue, EBITDA margin, and EPS in year one.

Newcomers· Sep 10

The company Axogen, Inc. (AXGN) is acquiring BioCircuit Technologies for $200M in cash to expand its nerve repair portfolio, with the deal expected to close in Q4 2026.
Axogen priced a $208.7 million public offering at $42.50 per share to fund the acquisition, and the deal will add FDA-cleared NerveTape to the company's portfolio.
The acquisition is seen as a bullish signal for the company, with a strong buy signal from EquityScope and a potential upside of 28.8% to analyst target.

Generated by AI

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often

5d agoBenzinga

Jefferies Remains a Buy on AxoGen (AXGN)

Detailed price information for Axogen Inc (AXGN-Q) from The Globe and Mail including charting and trades.

13d agoThe Globe and Mail

Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and Definium Therapeutics (DFTX)

Tipranks Press Release.

15d agoThe Globe and Mail

Axogen deepens nerve repair portfolio through $200m BioCircuit takeover

Through its BioCircuit buyout, Axogen hopes to extend the market uptake of the former’s NerveTape, a sutureless peripheral nerve repair device.

18d agoYahoo Finance

Also Discussed

Investors talking about AXGN also mention

#	Name	Attention
1	SMI 3Fourteen Full-Cycle Trend ETFFCTE	0%0
2	Viomi Technology Co Ltd ADRVIOT	0%new
3	Koninklijke Philips N.V. ADRPHG	0%0
4	Nexxen International Ltd.NEXN	0%0
5	Independent Bank CorporationIBCP	0%new
6	NEOS Nasdaq-100 Hedged Equity Income ETFQQQH	0.11%+0.1
7	Voc Energy TrustVOC	0%0
8	Radcom Ltd.RDCM	0%new
9	Akso Health Group ADRAHG	0%0
10	Align Technology Inc.ALGN	0%new

AxoGen Inc

Healthcare
Medical Devices

Axogen, Inc. is a medical technology company focused on peripheral nerve regeneration and repair. Axogen develops and commercializes surgical solutions used by surgeons and healthcare providers to address nerve injuries caused by trauma, procedures, or disease. Its current product portfolio includes nerve allografts, nerve connectors, nerve protectors, nerve caps, and soft tissue membranes designed to support nerve reconstruction, protection, and functional restoration. The company serves hospitals, surgery centers, military hospitals, and specialists in reconstructive, hand, orthopedic, plastic, and oral and maxillofacial surgery. Axogen plays a specialized role in the medical devices market by offering targeted technologies for peripheral nerve care and by supporting clinical education around surgical treatment of nerve damage. Headquartered in Alachua, Florida, Axogen remains focused on a niche segment of regenerative medicine and surgical reconstruction.

Website

Location

13631 Progress Boulevard

Alachua, FL, 32615

United States

Social

What share of all stock conversation is about AXGN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% +0

Sep 10

Axogen, Inc. (AXGN) has agreed to acquire BioCircuit Technologies for $200M in cash, with the deal expected to close in Q4 2026.
The acquisition will add BioCircuit's FDA-cleared NerveTape sutureless nerve repair device to Axogen's portfolio, and is expected to boost growth and adjusted EBITDA margins in year one.
Axogen has priced a $208.7M public offering of common stock at $42.50 per share to fund the acquisition, with the company expected to have approximately zero long-term debt after the offering.

Generated by AI

Sentiment

Of the messages about AXGN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +18.18	96.05% +23.35
Bearish	0%	0%	0% -18.18	3.95% -23.35

Bullish· Apr 28

Axogen's Q1 2026 earnings report showed strong revenue growth, with a 26.6% YoY increase to $61.5M, beating its own historical trajectory.
The company's revenue growth is accelerating, with a significant increase in Q1 2026 compared to Q4 2025, and a projected 20%+ growth for the full year, targeting $270M in revenue.
Axogen's cash position has increased to $103.6M, and the company is expecting to be free cash flow positive for the full year, with a gross margin in the 74-76% range.

Bearish· Dec 18

AxoGen, Inc. (AXGN) is an overhyped company with a cash-burning business model, trading at 12x revenue, and a target price of $5.07, implying an 82% downside.
AXGN has a high short interest, with a short entry at $32 and a target price of $17, indicating a significant bearish sentiment in the market.
A recent bearish article on Seeking Alpha has contributed to AXGN's decline, with the stock dropping by as much as 29% and reaching a low of $19.21, with a target price of $5.07.

Generated by AI

Topics

Of the messages about AXGN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Technical Analysis	0%	0%	4.08%	38.32%
Announcements	50%	50%	93.88%	47.31%
Analysts	50%	50%	2.04%	8.53%
Controversies	0%	0%	0%	0.47%
Earnings	0%	0%	0%	3.86%
Macro	0%	0%	0%	1.52%

Earnings· Aug 1

AxoGen, Inc. (AXGN) reported earnings that beat EPS estimates by $0.09, but missed revenue expectations.
The company's EPS results were in-line with estimates, but revenue came in lower than anticipated.
AxoGen, Inc. (AXGN) reported a loss in EPS, in-line with expectations, but the specific loss amount is not stated.

Announcements· Sep 10

Axogen, Inc. ($AXGN) has agreed to acquire BioCircuit Technologies for $200M in cash to expand its nerve repair portfolio.
The acquisition is expected to boost growth and adjusted EBITDA margins in year one, with closing expected in Q4 2026.
Axogen has priced a $208.7 million public offering at $42.50 per share to fund the BioCircuit acquisition, which sent shares down 5.2% in premarket trading.

Generated by AI

Community

Of the messages about AXGN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	37.41%	44.64%
Newcomers	0%	0%	62.59%	55.36%

Regulars· Sep 10

Axogen, Inc. (AXGN) has agreed to acquire BioCircuit Technologies for $200M in cash, with the deal expected to close in Q4 2026, subject to conditions.
The acquisition is being funded by a $208.7M public offering of common stock, priced at $42.50 per share, with Axogen planning to offer 4.91M shares.
Analysts are positive on the deal, citing the addition of NerveTape, the first FDA-approved sutureless nerve repair device, which is expected to be accretive to revenue, EBITDA margin, and EPS in year one.

Newcomers· Sep 10

The company Axogen, Inc. (AXGN) is acquiring BioCircuit Technologies for $200M in cash to expand its nerve repair portfolio, with the deal expected to close in Q4 2026.
Axogen priced a $208.7 million public offering at $42.50 per share to fund the acquisition, and the deal will add FDA-cleared NerveTape to the company's portfolio.
The acquisition is seen as a bullish signal for the company, with a strong buy signal from EquityScope and a potential upside of 28.8% to analyst target.

Generated by AI

AxoGen

Social

Sep 10

Bullish· Apr 28

Bearish· Dec 18

Earnings· Aug 1

Announcements· Sep 10

Regulars· Sep 10

Newcomers· Sep 10

Truist reiterates Buy on AxoGen stock after Aetna coverage win

Raymond James raises AxoGen stock price target on growth outlook

10 Health Care Stocks Whale Activity In Today’s Session - Axogen (NASDAQ:AXGN), Hims & Hers Health (NYSE:

Jefferies Remains a Buy on AxoGen (AXGN)

Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and Definium Therapeutics (DFTX)

Axogen deepens nerve repair portfolio through $200m BioCircuit takeover

Also Discussed

AxoGen Inc

Company Information

Location

Truist reiterates Buy on AxoGen stock after Aetna coverage win

Raymond James raises AxoGen stock price target on growth outlook

10 Health Care Stocks Whale Activity In Today’s Session - Axogen (NASDAQ:AXGN), Hims & Hers Health (NYSE:

Jefferies Remains a Buy on AxoGen (AXGN)

Analysts Offer Insights on Healthcare Companies: AxoGen (AXGN) and Definium Therapeutics (DFTX)

Axogen deepens nerve repair portfolio through $200m BioCircuit takeover

Also Discussed

Social

Sep 10

Bullish· Apr 28

Bearish· Dec 18

Earnings· Aug 1

Announcements· Sep 10

Regulars· Sep 10

Newcomers· Sep 10